• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

DionyMed Announces Close of Acquisition with Innovative Industrial Properties for MMAC’s 1.83 Acre Los Angeles Campus

Share:

July 30, 2019

Toronto, Ontario, July 24, 2019 – DionyMed Brands Inc. (“DionyMed” or “Company”) (CSE: DYME) (OTCQB: DYMEF), a multi-state cannabis brands platform, today confirmed the official close of its previously announced acquisition of select assets from MM Esperanza 2 LLC, doing business as “MMAC,” and MMAC’s 1.83 acre Los Angeles cannabis campus, including retail, distribution, manufacturing and cultivation licenses, for the purchase price of US$13,067,000 in cash and US$6 million in DionyMed Series A Multiple Voting Shares to MMAC.
In conjunction with the close of the MMAC transaction, DionyMed has completed its sale-leaseback agreement with Innovative Industrial Properties, Inc. (NYSE: IIPR, “IIPR”), to purchase the Los Angeles cannabis campus for US$13 million and to enter into a long-term lease back of 15 years with two optional 5-year extensions. IIPR is also providing DionyMed up to US$2 million of capital to make improvements at the property.
The Los Angeles cannabis campus provides DionyMed:

  • A market leading, Southern California direct-to-consumer fulfillment center capable of supporting up to 600 cannabis delivery drivers
  • A dispensary storefront, distribution facility and manufacturing hub
  •  Premium indoor cultivation
  •  All property, leaseholds, equipment and licenses

DionyMed paid MMAC US$13,067,000 in cash and issued 55,374 (US$6 million) in DionyMed Series A Multiple Voting Shares. The shares issued to MMAC will be subject to a 120-day holding period and DionyMed has the right, but not the obligation, to repurchase the shares over the next 12 months for a 10% premium over the share price at closing of the transaction with MMAC.
Edward Fields, CEO of DionyMed, commented, “This acquisition strategically positions DionyMed as a leader in California’s cannabis market. By incorporating MMAC’s Southern California direct-to-consumer fulfillment center, distribution facility, manufacturing hub, cultivation facility and dispensary storefront, with our existing operational base in Northern California, DionyMed is positioned for long-term growth to serve the largest cannabis market in the country.”
To be added to the DionyMed e-mail distribution list, please e-mail DionyMed@kcsa.com with DionyMed in the subject line.

Date: July 30, 2019

Source: DionyMed

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • what’s changing with the EU’s Medical Device Regulation?what’s changing with the EU’s Medical Device Regulation?
  • Scripps Bigshot who Cofounded Synthorx Exits amid Mystery
  • Validic Announces High-Frequency Data Support, Delivering Minute-to-Minute Readings From Wearables, Home Health DevicesValidic Announces High-Frequency Data Support, Delivering Minute-to-Minute Readings From Wearables, Home Health Devices
  • Nutritional High Bolsters Its California Brand Portfolio With LOI to Acquire Leading California Edibles CompanyNutritional High Bolsters Its California Brand Portfolio With LOI to Acquire Leading California Edibles Company
  • Generex Biotechnology Expands Medical Device & Wound Care Portfolio with Acquisition of Regentys CorporationGenerex Biotechnology Expands Medical Device & Wound Care Portfolio with Acquisition of Regentys Corporation
  • Picard Medical, Inc. Acquires Mechanical Heart Replacement TechnologyPicard Medical, Inc. Acquires Mechanical Heart Replacement Technology
  • CBC Group-Backed Hasten Biopharma Successfully Completes Acquisition of Five Cardiovascular and Metabolism Drugs from TakedaCBC Group-Backed Hasten Biopharma Successfully Completes Acquisition of Five Cardiovascular and Metabolism Drugs from Takeda
  • Johnson & Johnson under Pressure as FDA Approves New use for XareltoJohnson & Johnson under Pressure as FDA Approves New use for Xarelto

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications